We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Study of Nimotuzumab to Treat Colorectal Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by Peking University.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: September 7, 2009
Last Update Posted: September 7, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Biotech Pharmaceutical Co., Ltd.
Information provided by:
Peking University
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with advanced colorectal cancer.

Condition Intervention Phase
Advanced Colorectal Cancer Drug: Nimotuzumab and chemotherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras

Resource links provided by NLM:

Further study details as provided by Peking University:

Primary Outcome Measures:
  • Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated. [ Time Frame: within study period ]

Secondary Outcome Measures:
  • To determine the complete response rate, partial rate, disease response rate, disease control rate in the patients subject to treatment [ Time Frame: 3 months ]

Estimated Enrollment: 48
Study Start Date: June 2009
Estimated Study Completion Date: April 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Nimotuzumab and chemotherapy

    Experimental: Nimotuzumab and Irinotecan

    the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)

    the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)

    Other Name: Nimotuzumab
Detailed Description:
Nimotuzumab and Irinotecan will be administered to the patient until disease progression or development of toxicity preclude further treatment.Irinotecan will be administered once every 14 days,the dosage is 180mg/m2; Nimotuzumab treatment be divided 3 levels:200mg/w,400mg/w,600mg/w,weekly.The patients'blood test and liver and renal function tests will be monitored weekly, a physical exam and reassessment of the tumor will be performed and every 6 weeks,when the total result is the CR or PR, the result of the 6th and the 12th week should be compared.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent form signed before performing any of the study's specific procedures.
  • ECOG performance status 0-2.
  • Age > 18,both genders.
  • Metastatic colorectal cancer confirmed by pathology, or locally advanced unresectable colorectal cancer, or postoperative recurrence and metastasis colorectal cancer
  • Disease progression after receiving oxaliplatin ± fluorouracil in first-line treatment
  • At least 1 measurable lesions ,( longest diameter≥ 1 cm by spiral computed tomography (CT) scan or MRI)
  • Life expectancy more than 3 months.
  • K-ras is wild type
  • Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy.
  • Liver metastasis, lesions smaller than 50% of the liver; Lung metastasis, lesions smaller than 30% of the lung
  • Haemoglobin≥90g/L , granulocyte≥1.5×109/L ,WBC ≥3×109/L, platelet count≥100×109/L
  • TBIL≤ 1.5 x ULN ,ALK≤ 2.5 x ULN or ≤ 5ULN(Liver metastasis),AST and ALT≤ 2.5 x ULN or ≤ 5ULN(Liver metastasis),Creatinine ≤ 1.5 x ULN
  • No brain metastasis

Exclusion Criteria:

  • Previous radiotherapy at lesions within three months
  • Other first line chemo-agents treatment except oxaliplatin ± fluorouracil
  • Received other anti EGFR monoclonal antibody treatment
  • Complete or incomplete intestinal obstruction
  • Participation in other interventional clinical trials within 1 month
  • Psychiatric disease affected cognitive ability, including brain metastasis
  • Peripheral neuropathy lesion is more than I stage
  • History of serious allergic or allergy
  • Pregnant or breast-feeding women
  • Patients with the history of Serious lung or hear disease
  • Other malignant tumor
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00972465

Contact: Shen Lin 86-01-88196561

China, Guangdong
Sun Yat-Sen University Cancer Center Not yet recruiting
Guangzhou, Guangdong, China, 510060
Contact: ruihua Xu, M.D., Ph.D.    13922206676    xurh@mail.sysu.edu.cn   
Peking University, School of Oncology, Beijing Cancer Hospital & Institute Recruiting
Beijing, China
Contact: Jun Zhou, MD. PhD    88196088    joelbmu@126.com   
China People's Liberation Army (PLA)81 Hospital Not yet recruiting
Nanjing, China
Contact: Shukui Qin    13905158713    qinshukui@csco.org.cn   
Sponsors and Collaborators
Peking University
Biotech Pharmaceutical Co., Ltd.
Principal Investigator: Shen Lin Department of GI Oncology,Peking University, School of Oncology, Beijing Cancer Hospital & Institute
  More Information

Responsible Party: Shen Lin, Department of GI Oncology,Peking University, School of Oncology, Beijing Cancer Hospital & Institute
ClinicalTrials.gov Identifier: NCT00972465     History of Changes
Other Study ID Numbers: BT-CRC-T
First Submitted: September 4, 2009
First Posted: September 7, 2009
Last Update Posted: September 7, 2009
Last Verified: September 2009

Keywords provided by Peking University:
nimotuzumab colorectal cancer chemotherapy

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action